Concentration of Vascular Endothelial Growth Factor After Intracameral Bevacizumab Injection in Eyes With Neovascular Glaucoma
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To study the concentration of vascular endothelial growth factor (VEGF) in the aqueous humor before and after intracameral injection of bevacizumab in eyes with neovascular glaucoma, and to detect the duration of an anti-VEGF effect of bevacizumab in the anterior chamber. Methods: In this prospective interventional case series, 1.25 ㎎ of bevacizumab was injected into the anterior chamber of five eyes in five neovascular glaucoma patients. Aqueous humor samples were obtained just before intracameral injection of bevacizumab and two weeks after injection. The concentrations of VEGF in the aqueous humor were measured using ELISA. To investigate corneal endothelial damage after intrecameral bevacizumab injection, specular microscopy was performed before injection and two weeks after injection. Slit lamp photo and iris fluorescent angiography was performed to determine the regression of iris neovascularization. Results: After injection, substantial regression of neovascularization or fluorescein leakage was seen in all treated eyes. The VEGF concentrations in the aqueous humor in eyes with NVG were 1181.8±1248.3 pg/㎖ before intracameral injection of bevacizumab. Two weeks after injection, the VEGF concentrations decreased to 33.2±12.2 pg/ ㎖ (p=0.04, Wilcoxon signed rank test). There were no significant changes in IOP or corneal endothelial cells. Conclusions: Intracameral bevacizumab injection can remarkably reduce iris neovascularization in neovascular glaucoma patients. VEGF levels were significantly decreased two weeks after injection and corneal toxicity was not observed during short term follow-up.
Abstract
Purpose: To study the concentration of vascular endothelial growth factor (VEGF) in the aqueous humor before and after intracameral injection of bevacizumab in eyes with neovascular glaucoma, and to detect the duration of an anti-VEGF effect of bevacizumab in the anterior chamber. Methods: In this prospective interventional case series, 1.25 ㎎ of bevacizumab was injected into the anterior chamber of five eyes in five neovascular glaucoma patients. Aqueous humor samples were obtained just before intracameral injection of bevacizumab and two weeks after injection. The concentrations of VEGF in the aqueous humor were measured using ELISA. To investigate corneal endothelial damage after intrecameral bevacizumab injection, specular microscopy was performed before injection and two weeks after injection. Slit lamp photo and iris fluorescent angiography was performed to determine the regression of iris neovascularization. Results: After injection, substantial regression of neovascularization or fluorescein leakage was seen in all treated eyes. The VEGF concentrations in the aqueous humor in eyes with NVG were 1181.8±1248.3 pg/㎖ before intracameral injection of bevacizumab. Two weeks after injection, the VEGF concentrations decreased to 33.2±12.2 pg/ ㎖ (p=0.04, Wilcoxon signed rank test). There were no significant changes in IOP or corneal endothelial cells. Conclusions: Intracameral bevacizumab injection can remarkably reduce iris neovascularization in neovascular glaucoma patients. VEGF levels were significantly decreased two weeks after injection and corneal toxicity was not observed during short term follow-up.
참고문헌 (18)
- Tripathi RC, "Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma", Ophthalmology, 105, pp.232~237 (1998)
- Chalam KV, "Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma", Eur J Ophthalmol, 18, pp.255~262 (2008)
- Glaser BM, "Extracellular modulating factors and the control of intraocular neovascularization", Arch Ophthalmol, 106, pp.603~607 (1988)
- Sivalingam A, "Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy", Arch Ophthalmol, 108, pp.869~872 (1990)
- Tripathi RC, "Growth factors in the aqueous humor and their clinical significance", J Glaucoma, 3, pp.248~258 (1994)
- Meyer-Schwickerath R, "Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye diseases: studies in nondiabetic and diabetic subjects", J Clin Invest, 92, pp.2620~2625 (1993)
- Tripathi RC, "Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma", Ophthalmology, 105, pp.232~237 (1998)
- Hurwitz H, "Bevacizumab plus irinotecan, fluorouracil, and leucovorin formetastatic colorectal cancer", N Engl J Med, 350, pp.2335~2342 (2004)
- Aiello LP, "Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders", N Engl J Med, 331, pp.1480~1487 (1994)
- YazdaniS, "Intravitreal bevacizumab (Avastin) injection for neovascular Glaucoma", J Glaucoma, 16, pp.437~439 (2007)
- Sivack-Callcott JA, "Evidence based recommendations for the diagnosis and treatment of neovascular glaucoma", Ophthalmology, 108, pp.1767~1776 (2001)
- Ng EW, "Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration", Can J Ophthalmol, 40, pp.352~368 (2005)
- Tolentino MJ, "Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate", Arch Ophthalmol, 114, pp.964~970 (1996)
- Milko E, "Intravitreal Bevacizumab (Avastin®) in the Treatment of Neovascular Glaucoma", Am J Ophthalmol, 142, pp.1054~1056 (2006)
- 맹효성, "초기 신생혈관 녹내장에서 Bevacizumab (Avastin?)를 이용한 치료 1예", 대한안과학회지, 49(4), pp.696~700 (2008), 대한안과학회
- Sawada O, "Vascular Endothelial Growth Factor in Aqueous Humor Before and After Intravitreal Injection of Bevacizumab in Eyes With Diabetic Retinopathy", Arch Ophthalmol, 125, pp.1363~1366 (2007)
- Chiang CC, "Effect of Bevacizumab on Human Corneal Endothelial Cells: A Six-month Follow-up Study", Am J Ophthalmol, 146, pp.688~691 (2008)
- Yoeruek E, "Safety Profile of Bevacizumab on Cultured Human Corneal Cells", Cornea, 26, pp.977~982 (2007)